Infographics
Pulmonary Arterial Hypertension Summary:Pulmonary Arterial Hypertension (PAH) is a form of pre-capillary pulmonary hypertension (PH) defined by a mean pulmonary artery pressure (mPAP) > 20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and pulmonary vascular resistance (PVR) ≥ 3 Woods units. PAH can be caused by various conditions,…
INOCA: Ischemia and Non-Obstructive Coronary Artery Disease Summary:INOCA refers to symptoms of ischemia without obstructive coronary artery disease (CAD) or flow-limiting disease on left heart catheterization. The prevalence is significant, affecting 3-4 million people in the US, with around 70% of anginal hospitalizations showing non-obstructive CAD findings. It predominantly impacts…
Bleeding Academic Research Consortium (BARC) Scale Summary:The BARC Scale is a standardized tool used to categorize and define bleeding events in clinical trials. It spans from Type 1, which includes minor bleeding events that do not require medical intervention, to Type 5, indicating fatal bleeding. This scale helps clinicians assess…
Mavacamten: Novel Therapeutic Agent for Obstructive Hypertrophic Cardiomyopathy (HCM) Mavacamten is a new allosteric inhibitor of cardiac myosin ATPase, designed to reduce sarcomere hypercontractility, a key mechanism in obstructive hypertrophic cardiomyopathy. By decreasing actin-myosin cross-bridge interactions, Mavacamten helps to attenuate contractility, relieve left ventricular outflow tract (LVOT) obstruction, and improve…
The METEORIC-HF Study: The Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure with Reduced Ejection Fraction Summary:The METEORIC-HF study investigated whether Omecamtiv Mecarbil, a selective cardiac myosin activator, could improve exercise capacity in patients with HFrEF. Results showed no significant improvement in exercise capacity metrics, indicating that…
PROMPT-HF: Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice The PROMPT-HF trial tested the effectiveness of electronic medical record (EMR) alerts in improving the prescription of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). Results indicated that these alerts significantly increased GDMT prescription rates,…
EMPULSE: Empagliflozin in Patients Hospitalized for Acute Heart Failure EMPULSE assessed the effects of empagliflozin, an SGLT2 inhibitor, on patients hospitalized for acute heart failure (AHF). The study showed that empagliflozin significantly improved clinical outcomes, survival, and quality of life for patients hospitalized with AHF, regardless of baseline physical impairment,…
The DIAMOND Study: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi for HFrEF Summary:This study evaluated the role of Patiromer in enabling patients with heart failure with reduced ejection fraction (HFrEF) and hyperkalemia to maintain optimal RAAS inhibitor therapy. The findings suggested that Patiromer allowed patients to stay…
The SODIUM-HF Trial: Study of Dietary Intervention Under 100 MMOL in Heart Failure The SODIUM-HF study aimed to evaluate the effect of a low-sodium diet compared to usual care on outcomes for patients with heart failure (HF), regardless of left ventricular ejection fraction (LVEF). Although the low-sodium diet did not…
2022 AHA/ACC/HFSA Heart Failure Management Guidelines - Value Statements This infographic outlines the economic value statements from the 2022 AHA/ACC/HFSA guidelines for heart failure management, helping to prioritize recommendations based on cost-effectiveness and quality of life impact. It categorizes treatments into high, intermediate, and low economic value, aiding clinicians in…